MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.760
+0.010
+0.57%
Opening 10:16 04/14 EDT
OPEN
1.750
PREV CLOSE
1.750
HIGH
1.760
LOW
1.720
VOLUME
123.53K
TURNOVER
--
52 WEEK HIGH
2.960
52 WEEK LOW
1.520
MARKET CAP
399.88M
P/E (TTM)
-24.4784
1D
5D
1M
3M
1Y
5Y
Global Microbial Technology Product MarketSize, Share, Value, and Competitive Landscape 2020
Apr 12, 2021 (Heraldkeepers) -- Global Microbial Technology Product Market Overview:Global Microbial Technology Product Market Report 2020 comes with the...
Heraldkeepers · 1d ago
Global Cannula Holders Market 2021 Analytical Assessment, Key Drivers, Growth and Opportunities to 2026
Apr 12, 2021 (CDN Newswire via Comtex) -- Global Cannula Holders Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 introduced by...
CDN Newswire · 1d ago
Primary Sclerosing Cholangitis Market 2020-2027 Analysis by Regional Development Status, Market Size, Market Dynamics, Applications
Apr 10, 2021 (Market Insight Reports) -- Primary Sclerosing Cholangitis Market to Reach US$ 140.4 Million by 2023 – Coherent Market Insights Global Primary...
Market Insight Reports · 4d ago
Global Disruptive Behavior Disorders Market Growth, Status and Outlook Research Report 2021-2026
Apr 07, 2021 (Heraldkeepers) -- The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size...
Heraldkeepers · 6d ago
Cannula Holders Market 2021 Global Industry Size, Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2026
The Express Wire · 04/06 18:52
Global Calming and Sleeping Market Outlook, Industry Analysis and Prospect 2021
Apr 06, 2021 (Heraldkeepers) -- The research report includes specific segments by region (country), by company, by Type and by Application. This study...
Heraldkeepers · 04/06 10:59
Global Transmucosal Drug Delivery Market Growth 2021-2027 with Top Countries Data: Industry Insights by Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen | With Covid-19 Analysis
Apr 05, 2021 (The Expresswire) -- Global “Transmucosal Drug Delivery Market” research report (2021-2027) covers the market outline and topographical...
The Express Wire · 04/05 05:03
Transmucosal Drug Delivery Market Provides an In-Depth Insight of Sales, Revenue, Analysis of Growth Factors and Upcoming Trends, Opportunities by Types and Application to 2025 Says Industry Research Biz
Mar 30, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The global “Transmucosal Drug Delivery...
The Express Wire · 03/30 05:10
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRRX stock price target is 6.67 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 148
Institutional Holdings: 140.81M
% Owned: 61.98%
Shares Outstanding: 227.20M
TypeInstitutionsShares
Increased
41
2.47M
New
13
3.04M
Decreased
28
3.37M
Sold Out
17
1.54M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.47%
Pharmaceuticals & Medical Research
+0.95%
Key Executives
Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Chief Financial Officer
Michael Arenberg
Senior Vice President
Judy Joice
Other
Norman Sussman
Director
Mohammad Azab
Director
Gail Maderis
Independent Director
Simon Benito
Independent Director
Terrence Blaschke
Independent Director
Gail Farfel
Independent Director
Armand Neukermans
Independent Director
Judith Robertson
Independent Director
Jon Saxe
No Data
  • All
  • Financials
  • Insiders
More
About DRRX
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.